Stem Cell Therapeutics appoints three new members to board of directors

Calgary, AB – Stem Cell Therapeutics announced today that Dr Tony Cruz, Don McCaffrey, and Jeffrey Shmigelsky have been appointed to its board of directors.

“These key appointments bring extensive knowledge and essential contacts that will advance our market competitiveness and enhance our plans to move the company’s therapeutic products through development into commercialization,” said Dr Joseph Tucker, the company’s president and CEO.

Dr Cruz is the chairman, CEO and founder of biotech firm Transition Therapeutics. He was the vice-president, director, and founder of Angiotech Pharmaceuticals and has also been senior scientist at Mount Sinai Hospital since 1995 and was the CEO and president of the Canadian Arthritis Network from 1997 to 2001.

Mr McCaffrey is president and CEO of Resverlogix. He was president of the BioFuture Conference which was a national biotechnology event hosting biotechnology researchers, financiers and industry speakers.

Mr Shmigelsky is the founder and former president of CADVision Internet, an Internet service provider in Calgary. He is currently CEO of Launch Vision Research, a high-tech incubator and venture capital firm.